Literature DB >> 32219571

Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer.

Jie Yang1.   

Abstract

Gastric cancer (GC) is one of the most common malignant tumors in the world, and it is also the third largest cause of cancer-related death in the world. As far as we know, no biomarker has been widely accepted for early diagnosis and prognosis prediction of gastric cancer. The purpose of this study is to find potential biomarkers to predict the prognosis of GC. The gene expression profiles of GSE2685 were downloaded from GEO database. Morpheus was used to calculate the differentially expressed genes (DEGs) between primary advanced gastric cancer tissues and noncancerous gastric tissues. The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) enrichment analyses were performed, and protein-protein interaction (PPI) network of DEGs was constructed. Kaplan-Meier Plotter was used to determine the overall survival (OS) outcomes of UC5AC, MUC1, KRT7, GAPDH, CD44, and GEPIA was used to determine the Pearson correlation analysis. In total, 710 DEGs were identified in GC, including 396 upregulated genes and 314 downregulated genes. GO enrichment revealed that they were mainly enriched in binding, catalytic activity, cellular process and cell. KEGG pathway revealed that they were mainly enriched in metabolic pathways, pathways in cancer and PI3K-Akt signaling pathway. MUC5AC, MUC1, KRT7, GAPDH, CD44 were identified from the PPI network. MUC5AC, MUC1, KRT7, GAPDH, CD44 were demonstrated to have prognostic value for patients with GC. MUC5AC, MUC1 exhibited low expression levels in GC tissues, KRT7, GAPDH, CD44 presented high expression levels in GC tissues. In particular, KRT7 is hardly expressed in normal gastric tissues. MUC5AC and MUC1 were negatively correlated with GAPDH, CD44, respectively; and GAPDH was positively correlated with CD44 and KRT7, respectively. Moreover. MUC5AC, MUC1, KRT7, GAPDH, and CD44 are not only related to GC but also to apoptosis pathway. Results from the present study suggested that MUC5AC, MUC1, KRT7, GAPDH, CD44 may represent novel prognostic biomarkers for GC.

Entities:  

Keywords:  Biomarker; Differentially expressed genes; Gastric cancer; Microarray

Year:  2020        PMID: 32219571     DOI: 10.1007/s12032-020-01362-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  65 in total

1.  Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer.

Authors:  Ece Dilege; Mehmet Mihmanli; Uygar Demir; Kadir Ozer; Ozgür Bostanci; Cemal Kaya; Oznur Aksakal; Damlanur Sakiz
Journal:  Hepatogastroenterology       Date:  2010 May-Jun

2.  The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy.

Authors:  Dae Hoon Kim; Seung Jong Oh; Cheong Ah Oh; Min Gew Choi; Jae Hyung Noh; Tae Sung Sohn; Jae Moon Bae; Sung Kim
Journal:  J Surg Oncol       Date:  2011-06-21       Impact factor: 3.454

3.  Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer.

Authors:  L Setälä; P Lipponen; R Tammi; M Tammi; M Eskelinen; E Alhava; V M Kosma
Journal:  Histopathology       Date:  2001-01       Impact factor: 5.087

4.  Identifying novel biomarkers of gastric cancer through integration analysis of single nucleotide polymorphisms and gene expression profile.

Authors:  Tao Wang; Yan Xu; Peng Hou
Journal:  Int J Biol Markers       Date:  2015-07-22       Impact factor: 2.659

5.  FOXA1 promotes proliferation, migration and invasion by transcriptional activating KRT7 in human gastric cancer cells.

Authors:  B L Liu; J J Qin; W Q Shen; C Liu; X Y Yang; X N Zhang; F Hu; G M Liu
Journal:  J Biol Regul Homeost Agents       Date:  2019 Jul-Aug       Impact factor: 1.711

6.  Gene expression profile towards the prediction of patient survival of gastric cancer.

Authors:  Zhen-Yu Xu; Jia-Shun Chen; Yong-Qian Shu
Journal:  Biomed Pharmacother       Date:  2009-11-13       Impact factor: 6.529

7.  Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer.

Authors:  Atsushi Takeno; Ichiro Takemasa; Shigeto Seno; Makoto Yamasaki; Masaaki Motoori; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Yoshiyuki Fujiwara; Toshiro Nishida; Toshitsugu Okayama; Kenichi Matsubara; Yoichi Takenaka; Hideo Matsuda; Morito Monden; Masaki Mori; Yuichiro Doki
Journal:  Ann Surg Oncol       Date:  2009-12-11       Impact factor: 5.344

8.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Jean-Francois H Geschwind; Rani Kunjithapatham; Manon Buijs; Josephina A Vossen; Irina Tchernyshyov; Robert N Cole; Labiq H Syed; Pramod P Rao; Shinichi Ota; Mustafa Vali
Journal:  Anticancer Res       Date:  2009-12       Impact factor: 2.480

9.  Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection.

Authors:  Kwang Kuk Park; Song I Yang; Kyung Won Seo; Ki Young Yoon; Sang Ho Lee; Hee Kyung Jang; Yeon Myeong Shin
Journal:  Gastroenterol Res Pract       Date:  2015-04-28       Impact factor: 2.260

10.  Prevalence of Her3 in gastric cancer and its association with molecular prognostic markers: a Saudi cohort based study.

Authors:  Ayesha Ahmed
Journal:  Libyan J Med       Date:  2019-12       Impact factor: 1.657

View more
  8 in total

1.  A Network Pharmacology Study Based on the Mechanism of Citri Reticulatae Pericarpium-Pinelliae Rhizoma in the Treatment of Gastric Cancer.

Authors:  Siyuan Song; Wenjie Huang; Xiaona Lu; Jiatong Liu; Jiayu Zhou; Ye Li; Peng Shu
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-16       Impact factor: 2.629

2.  A Dual, Systematic Approach to Malaria Diagnostic Biomarker Discovery.

Authors:  Seda Yerlikaya; Ewurama D A Owusu; Augustina Frimpong; Robert Kirk DeLisle; Xavier C Ding
Journal:  Clin Infect Dis       Date:  2022-01-07       Impact factor: 9.079

3.  The prognostic value of arginase-1 and glypican-3 expression levels in patients after surgical intrahepatic cholangiocarcinoma resection.

Authors:  Zeyuan Qiang; Haofeng Zhang; Shuai Jin; Cao Yan; Zhen Li; Lianyuan Tao; Haibo Yu
Journal:  World J Surg Oncol       Date:  2021-10-29       Impact factor: 2.754

4.  High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality.

Authors:  Charles Dariane; Sylvie Clairefond; Benjamin Péant; Laudine Communal; Zhe Thian; Véronique Ouellet; Dominique Trudel; Nazim Benzerdjeb; Feryel Azzi; Arnaud Méjean; Marc-Olivier Timsit; Manon Baurès; Jacques-Emmanuel Guidotti; Vincent Goffin; Pierre I Karakiewicz; Anne-Marie Mes-Masson; Fred Saad
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

5.  The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days.

Authors:  Zhi Zheng; Jung Kuk Park; Oh Wook Kwon; Sung Hoon Ahn; Young Joo Kwon; Linjuan Jiang; Shaohui Zhu; Byoung Hee Park
Journal:  J Korean Med Sci       Date:  2022-08-01       Impact factor: 5.354

6.  A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.

Authors:  Laudine Communal; Noemi Roy; Maxime Cahuzac; Kurosh Rahimi; Martin Köbel; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

7.  A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer.

Authors:  In-Seob Lee; Jiyoung Ahn; Kwangsoo Kim; Yoshinaga Okugawa; Yuji Toiyama; Hoon Hur; Ajay Goel
Journal:  Br J Cancer       Date:  2021-06-23       Impact factor: 9.075

Review 8.  MUC1 is an oncoprotein with a significant role in apoptosis (Review).

Authors:  Katarzyna Supruniuk; Iwona Radziejewska
Journal:  Int J Oncol       Date:  2021-07-19       Impact factor: 5.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.